Early Efficacy and Safety of the Third Dose Inactivated COVID-19 Vaccine among People Living with HIV

SARS-CoV-2 may exist longer in vivo and further be more likely to mutate and evolve in advanced HIV infection. Therefore, it is crucial to protect people living with HIV (PLWH) from SARS-CoV-2 infection. Booster vaccination is needed because of the waning immunity to primary two-dose COVID-19 vaccines and the immune response weakened by SARS-CoV-2 variants, especially for immunosuppressed populations. In our previous study, we found that the early humoral immune responses to primary two-dose inactivated COVID-19 vaccines in PLWH were weaker than those in healthy individuals, and the adverse reactions between the 2 groups were comparable. Currently, it is still unclear whether PLWH will benefit more from a booster dose of inactivated COVID-19 vaccines. Here, we conducted a prospective study to evaluate the early antibody responses and safety of the third dose inactivated COVID-19 vaccines among PLWH on stable antiretroviral therapy